• V Sidi, G Arsos, E Papakonstantinou, E Hatzipantelis, I Fragandrea, N Gombakis, and E Koliouskas.
• Department of Pediatric Oncology, Hippokration General Hospital of Thessaloniki, and Department of Nuclear Medicine, Aristotle University School of Medicine, Thessaloniki, Greece. paedonc@ippokration.gr
• Hippokratia. 2007 Jan 1; 11 (1): 252925-9.

AimPreclinical and clinical evaluation of amifostine (AMI) administration in conjunction with systemic chemotherapy supports its role as a cytoprotective agent of normal tissues without loss of impairing the antitumour effectiveness of chemotherapeutic agents. Since only a limited number of clinical studies has been performed using AMI in paediatric pts with malignancies we investigated the protective effect of AMI against carboplatin-induced myelotoxicity and nephrotoxicity in a paediatric group of patients.Material And ResultsAMI was administered in 18/28 paediatric patients with reccurent solid tumours along with ICE (ifosfamide, carboplatin, etoposide) chemotherapy. A significant (p<0.05) decrease in GFR was observed in the control group whereas it was maintained at pre-treatment levels in the AMI-treated group. Leukopenia and neutropenia were significantly (p<0.05) less in AMI-group. No protective effect of AMI was shown concerning thrombocytopenia.ConclusionsAMI was generally well tolerated at the dose of 740 mg/m2. Side effects including nausea, vomiting, hypotension, flushing and rigors were moderate and reversible and the interruption of infusion was never required.

5 keywords...

hide…